The split between AstraZeneca and Abraxis over their copromotion of cancer drug Abraxane was expected among some Abraxis reps since August of this year. Now it's official. The end of the agreement ...

NEW YORK (AP) — Biotechnology company Celgene said Wednesday that it is expanding its array of cancer treatments with a deal to buy Abraxis BioScience for $2.9 billion in cash and stock. Celgene said ...

Call it a case of hindsight. Abraxis Bioscience and AstraZeneca are poised to end their two-year marketing partnership on the breast cancer treatment Abraxane, which cost Astra $200 million back in ...

Abraxis BioScience, Inc. and ProMetic Life Sciences Inc. (PFSCF.PK) Enter License Agreements for Up to $295M US For Four Biopharmaceuticals Abraxis Makes Initial $7 M US Equity Investment in ProMetic, ...

Abraxis Bioscience gained 28.6% on Thursday after the drugmaker announced its lung cancer treatment Abraxane met the goals of its late-stage study. The Los Angeles-based company said the study ...

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that the Board of Directors has approved a strategic plan to create Abraxis Health, Inc., an ...

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that Leon (Lonnie) O. Moulder, Jr., has been appointed Vice Chairman, ...

Abraxis BioScience Inc. said on Thursday that it has signed agreements with ProMetic Life Sciences Inc. to develop and commercialize four of the Canadian biotech’s products that target underserved ...

Abraxis BioScience, Inc. has announced an agreement with the Buck Institute for Age Research that provides Abraxis with the exclusive worldwide intellectual property rights for technologies designed ...

Biotechnology company Celgene (CELG) announced it is buying Abraxis BioScience (ABII) for $2.9 billion in cash and stock. With this acquisition, Ceglene is expanding its portfolio of cancer treatments ...